IL1B and neoplasm: In tumour-naïve mice, a single dose of Anakinra reduces osteoclast and osteoblast activity in addition to causing a reduction in IL-1B and TNFa levels indicating that in addition to anti-tumour effects of Anakinra, this drug may also target bone cells thus reducing resorption and availability of bone-derived growth factors that can further stimulate tumour growth.